In a cohort of 88 NSCLC patients treated with anti-PD-1 antibodies, the EV-miR-625-5p level was found to act as an independent biomarker of response and survival in ICI-treated NSCLC patients, in particular in patients with PD-L1 expression ≥ 50% [159]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.